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One of the prices we pay for our love of jewelry is aller-
gic contact hypersensitivity to metal, an autoimmune con-
dition that variably afflicts around 10% of all Caucasians (1).
Contact hypersensitivity is a classic type IV DTH (delayed
type hypersensitivity) response, involving primed T cells
that are specific for metal modified antigens generated at a
local site in the body (most commonly the epidermal layer
of the skin). The T cells respond by producing proinflamma-
tory mediators that result in local redness, swelling, and
itching (2). In many cases nickel is found to be the cul-
prit and unfortunately for sensitive people, nickel is one of
the most common metals in the environment, which
makes it particularly difficult to avoid. Being a ubiquitous
component of metal alloys, nickel is found not only in
catheters, needles, dental braces, and many other medical
devices, but also in everyday items such as jewelry,
watches, coins, and even in some foods. Cases can range in
severity from a mild localized swelling, redness, and itchi-
ness to a much more debilitating reaction involving larger
areas (e.g., the entire mouth in some patients with hyper-
sensitivity to the metal of their dental braces). Ni
 
2
 
 
 
 reactive
T cell clones have been isolated from patients and found to
display varying degree of MHC class II restriction (some
are more promiscuous than others) and two models have
been advanced to explain what might be happening at the
molecular level (3). The first model (Fig. 1) proposes that
Ni
 
2
 
 
 
 derivatized self-proteins are naturally processed and
presented as Ni
 
2
 
 
 
/peptides by the APC resident in the skin
(e.g., Langerhan cells). The second model proposes a pro-
cessing independent pathway where the metal directly de-
rivatizes MHC peptide complexes on the surface of the
APC. While both mechanisms seem feasible, firm evidence
for either has been elusive . . .  until now. In this issue, Lu
et al. (4), present direct evidence for the formation of a pre-
formed HLA-DR/Ni
 
2
 
 
 
 complex that stimulates a Ni
 
2
 
 
 
 re-
active human T cell clone called ANi-2.3. ANi-2.3 is a
CD4
 
 
 
 T cell with a V
 
 
 
17/V
 
 
 
1 T cell receptor and is re-
stricted by HLA-DR52c pretreated with soluble Ni
 
2
 
 
 
. Us-
ing mutagenesis, they localize the Ni
 
2
 
 
 
 binding site to his-
tidine 81 on top of MHC class II 
 
 
 
-chain. His81 is familiar
to anyone who has worked with bacterial superantigens be-
cause it’s the same residue targeted by a subset of bacterial
superantigens using a Zn
 
2
 
 
 
 atom to bind tightly to MHC
class II (5). His81 is one of only a few conserved residues
on the top of the MHC class II and plays an important role
in stabilizing bound peptide through a hydrogen bond to
the peptide backbone (6). The important feature of Zn
 
2
 
 
 
 in
superantigen binding is the stability it provides the MHC
class II/Sag complex, so the analogy between stable super-
antigen binding and metal-mediated TCR binding is clear
and important. The Lu paper reveals for the first time, a
possible molecular structure that might explain how nor-
mally tolerant, self-reactive T cells are stimulated into ac-
tion through the addition of a single metal atom on the top
of the MHC class II molecule.
 
How Do Metals Bind Proteins?
 
Every stage I biology stu-
dent knows that transition metals such as zinc, copper, iron
are essential components in many biochemical reactions.
Nickel on the other hand, has no known biological role in
humans but is used by some microbes; the best known be-
ing the two Ni
 
2
 
 
 
 atoms at the active site of bacterial urease
(see the PDB structure 2UBP and see Fig. 2). Transition
metals form coordination complexes with the imidazole ni-
trogens of histidine, the carbonyl group of aspartate or
glutamate or the free sulfur atom of cysteine amino acids.
Like Zn
 
2
 
 
 
 which is arguably the best-studied metal, Ni
 
2
 
 
 
has a coordinate number of 4. At least 3 amino acid side-
chains must be correctly spaced in a trigonal pyramid or
planar geometry to tether the metal ion to the protein sur-
face (see Fig. 2). Zn
 
2
 
 
 
 binds via a conserved motif L1 –
(X)
 
n
 
 – L2 – X
 
(1–2)
 
 – L3 with the critical component being
the strictly spaced L2-L3 bidendate ligand separated by ei-
ther 1 amino acid when present on a 
 
 
 
-strand or 2 amino
acids apart when on an 
 
 
 
-helix (7).
Ni
 
2
 
 
 
 binding sites are less well studied and subsequently,
no Ni
 
2
 
 
 
 binding motif has been proposed. There are a few
crystal structures of Ni
 
2
 
 
 
 protein complexes and these also
involve His and Asp in a square planar geometry to Zn
 
2
 
 
 
(see Fig. 2; references 8 and 9). However Ni
 
2
 
 
 
 and Zn
 
2
 
 
 
are not interchangeable so any comparison between these
two metals sitting on the top of an MHC class II molecule
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must remain speculative but because there are a number of
structures which detail how Zn
 
2
 
 
 
 binds to MHC class II at
His81, it would seem reasonable to discuss this in light of
the Lu paper. In the structure of the streptococcal superan-
tigen SPEC bound to HLA-DR (5), the Zn
 
2
 
 
 
 atom is pre-
bound to the superantigen by 3 amino acid side-chains in
trigonal pyramid geometry. A water molecule acts as the
4th ligand for Zn
 
2
 
 
 
 and is displaced in favor of His81 to
form a stable tetravalent complex buried within the hydro-
phobic core of the Sag/MHC interface (see Fig. 2). The
exclusion of water from the interface provides a stable and
long-lasting complex. Only His81 from the MHC class II is
involved in the metal coordination complex.
In the Lu paper, the authors propose that the Ni
 
2
 
 
 
 atom
is instead prebound to His81 on DR52c and that the other
two side-chain ligands come from self-peptide(s). The ra-
tionale for this is simply that there are no other His, Asp, or
Glu side-chains on the DR52c molecule close enough to
contribute. More importantly, ANi2.3 only responds to
Ni
 
2
 
 
 
 treated DR52c on human and mouse B cells but not
fibroblasts or other antigen presenting deficient cells.
Moreover, the authors are able to elute mixed peptides
from the APCs and show that these can be used to refur-
nish a Ni
 
2
 
 
 
 dependent response on acid-stripped, formalin-
fixed APCs. The sequence of these peptides is not revealed
in the paper and their identification will be critical in con-
firming this model.
The fact that presentation of Ni
 
2
 
 
 
 only occurs with cer-
tain peptides begs two questions. The most obvious is do
they have His, Asp, or Glu or even potentially Cys at the
NH
 
2
 
-terminal end adjacent to His81 and second; do certain
self-peptide MHC combinations predispose an individual
to Ni
 
2
 
 
 
 hypersensitivity – is this all that’s required to gener-
ate the disorder? Obviously not all Ni
 
2
 
 
 
 hypersensitive pa-
tients are HLA-DR52c (10% of Caucasians have metal hy-
persensitivity) but His81 is found in almost all HLA-DR
molecules so if this model holds as a predominant mecha-
nism for Ni
 
2
 
 
 
 induced DTH, are there a range of other
HLA class II peptide combinations that can mimic the pre-
sentation of Ni
 
2
 
 
 
 by DR52c? Direct sequencing of peptides
eluted from the purified DR52c would be one option to
identify these peptide(s) but this is risky as it assumes the
peptides in question are abundant enough to isolate and se-
quence. A quicker route might be to randomly test candi-
date synthetic peptide libraries based on a theoretical
DR52c motif with introduced His, Asp, and Glu residues at
positions adjacent to His81 (these are P1, P2, P3, or P4).
 
The Role of TCR in Metal Reactivity.
 
One can safely as-
sume that a reactive Ni
 
2
 
 
 
 ion perched on the top of the
MHC class II molecule is going to react in some way with
TCR - so how would this occur and alter the stability of
the complex formed? It is very unlikely that an MHC–
Ni
 
2
 
 
 
–TCR complex works in a similar fashion to Sag
activation where the metal atom alone promotes strong
binding irrespective of polymorphisms in the surrounding
interface. If this were the case, we would expect superanti-
gen-like oligoclonal T cell responses to Ni
 
2
 
 
 
. In fact, the
precursor frequency of Ni
 
2
 
 
 
 reactive clones in hypersensi-
tive patients is low implying that the binding energy
provided by a Ni
 
2
 
 
 
 complex is not in itself sufficient to
circumvent required complementarity between MHC–
peptide and TCR surfaces.
Figure 1. Two hypothetical pathways for nickel presentation. (1) Processing-dependent pathway. Nickel ions bind to self proteins which are then pro-
cessed and presented by MHC on Langerhan cells. (2) Processing-independent pathway. Nickel ions enter through the skin where they bind directly to
preformed MHC/peptide complexes on Langerhans cells.T
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The literature on this aspect of contact hypersensitivity is
awash with contradiction and unfortunately the Lu paper,
despite its importance, does little to clarify things at this
stage. There have been many Ni
 
2
 
 
 
 reactive T cells clones
studied over the years, but there doesn’t seem to be any
real consistency in their 
 
modus operandi
 
. They consistently
display varying degrees of MHC promiscuity or preference
for TCR chains that does not support a consistent model
for Ni
 
2
 
 
 
 derivatization of MHC class II at His81 as a pre-
dominant mechanism of metal hypersensitivity. One thing
that does appear consistent, is that they are mostly CD4
 
 
 
 T
cells and that they respond to Ni
 
2
 
 
 
 in the absence of CD4,
a sure sign of increased stability of the MHC–TCR com-
plex in the presence of Ni
 
2
 
 
 
 (10).
Several studies reveal that Ni
 
2
 
 
 
 reactive T cells (includ-
ing the ANi-2.3 used in the Lu et al. paper) prefer to use
TCR V
 
 
 
17 domain (11, 12). BV17 is very interesting be-
cause the CDR1 loop has a unique Histidine
 
29
 
-Aspartic
acid
 
30
 
 that would make an excellent bidentate metal bind-
ing site. Unfortunately, all crystal structures of MHC class
II:TCR complexes so far show that these residues would
be positioned over the MHC 
 
 
 
-chain; well away from a
Ni
 
2
 
 
 
 atom bound to His81. Unless the ANi2.3 TCR binds
in a reversed orientation on MHC class II (this would be
extremely interesting) a simple model of a metal complex
between His81 and two residues in BV17 can be dis-
counted – although the high frequency of BV17 in Ni
 
2
 
 
 
reactive clones needs to be explained somehow.
Previous mutagenesis studies of the ANi2.3 TCR and
other Ni
 
2
 
 
 
 reactive T cell clones implicate instead the
CDR3B region particularly Arg95Asp96 which when mu-
tated, abrogated ANi2.3 reactivity to Ni
 
2
 
 
 
 (10). This also
seems somewhat contradictory since these residues are also
not “over” His81 (remembering that the chelating atom in
the residue must be a mere 2 Å away from the metal atom).
The residues closest to His81 are in fact in the CDR1
 
 
 
loop. Looking at the ANi2.3 TCR, there is nothing in this
region that would immediately suggest a contribution as a
4th ligand for the Ni
 
2
 
 
 
 atom.
 
Immune Consequences.
 
Although the kinetics and exact
structure of the MHC/peptide-Ni
 
2
 
 
 
 interaction remains to
be determined, an analogous higher affinity-binding mode
would have a number of important consequences. For ex-
ample, certain MHC alleles have recently been found asso-
ciated with the sensitivity of an individual to the toxic ef-
fects of superantigens (13). Could the same be translated to
Ni
 
2
 
 
 
 sensitivity? Severe hypersensitivity reactions can be
related to overexpression of TCR V
 
 
 
17 but whether this
correlates to Ni
 
2
 
 
 
 reactivity itself or to the restricting MHC
class II molecules is unknown (11). Without question, a
DR52c crystal structure with Ni
 
2
 
 
 
 bound, will remove
much of the guesswork.
The paper by Lu et al. shows for the first time that de-
layed type hypersensitivity to Ni
 
2
 
 
 
 results from the direct
derivatization of the MHC class II molecule itself and that
unidentified self-peptide(s) are required to support the
Ni
 
2
 
 
 
-mediated response by providing additional ligands for
the metal complex. What is yet to be revealed is how
tightly the Ni
 
2
 
 
 
 is bound and whether other metals replace
it. What is so special about Ni
 
2
 
 
 
 as opposed to other met-
als? Simultaneous sensitivity to several metals is clinically
quite common. In particular Ni
 
2
 
 
 
-reactive T cell clones
Figure 2. Crystal structures of two known metal chelation sites. The first is the arrangement of the superantigen SPEC residues His167, His201, and
Asp203 and His81 from HLA-DR1 in a tetrahedral coordination around Zn2  (PDB 1HQR and reference 5). The distance from each atom to the Zn2 
is 1.8–2.0 Å. The second is the square planar coordination complex surrounding one of the Ni2  atoms found in the bacterial urease molecule (PDB -
2UBP and reference 8). The distance from the center of the Ni2  atom to each of the coordinating atoms is 2.1–2.3 Å so the Ni2  coordination site is
slightly larger.T
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can also respond to Pd
 
2
 
 
 
 and Cu
 
2
 
 
 
 and a common feature
of these metal ions is that they can adopt identical coordi-
nation geometry to Ni
 
2
 
 
 
 plus they have similar atomic ra-
dii. The discovery of the role of His81
 
 
 
 in Ni
 
2
 
 
 
 coordina-
tion certainly explains this metal cross-reactivity but it does
not entirely explain why Ni
 
2
 
 
 
 and not Cu
 
2
 
 
 
 is the more
common the culprit. Affinity binding and competition
studies might provide a quantitative explanation as to why
Ni
 
2
 
 
 
 is more effective at causing metal hypersensitivity.
 
Implications on the Processing-dependent Pathway.
 
While
the majority of metal reactive T cell clones such as ANi2.3
are processing independent, there is still a large proportion
(
 
 
 
40%) that are strictly processing dependent (2, 14)
meaning that Ni
 
2
 
 
 
 is not presented by formalin-fixed
APCs. Can the model described by Lu et al. explain both
pathways? It seems difficult to imagine how Ni
 
2
 
 
 
 deriva-
tized exogenous peptides can survive the tortuous route of
the exocytic pathway intact to be presented by MHC class
II. Perhaps processing is required to maintain an abundance
of a bound peptide that can sustain stable Ni
 
2  binding at
His81. One would predict that if an exogenous protein can
be derivatized before processing, then it could just as easily
be (more so in fact) derivatized as a peptide bound to
MHC class II. One simple way to test this question would
be to attempt to stimulate processing dependent Ni2  reac-
tive clones with MHC class II defective in His81.
Metal hypersensitivity and DTH responses are part of
the fabric of clinical immunology yet the underlying
mechanisms and molecular basis for this classic immune
disorder have remained elusive. The paper of Lu et al., of-
fers the first tangible model for what might be occurring at
the interface between MHC class II and TCR. There is
much that is tantalizingly absent from this paper that no
doubt will reveal itself in the fullness of time. Once the in-
dividual components have been isolated, biochemical and
biophysical measurements will provide quantitative infor-
mation about such things as how tightly Ni2  binds and
exactly how much the metal coordination complex im-
proves in the binding affinity of the TCR. As we have
pointed out, the paper does not resolve many of the ambi-
guities concerning TCR usage in Ni2  reactivity and in
fact creates a few more. What is important about this paper
is that for the first time, the metal atom has a definite loca-
tion on the top of MHC class II. One hopes that in the not
too distant future, there will be an all revealing three di-
mensional structure of Ni2  at the center of a DR52c:
ANi2.3 TCR complex.
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